Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers

BACKGROUND: T-cell receptor-engineered T cells (TCR-Ts) have achieved encouraging success in anticancer clinical trials. The antigenic targets, however, were primarily focused on human leukocyte antigen (HLA) A*02:01 restricted epitopes from a few cancer/testis antigens (CTAs) which are not widely e...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qingyang, Hu, Wei, Liao, Baoyi, Song, Chanchan, Li, Liangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263944/
https://www.ncbi.nlm.nih.gov/pubmed/35798537
http://dx.doi.org/10.1136/jitc-2022-004713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263944/
https://www.ncbi.nlm.nih.gov/pubmed/35798537
http://dx.doi.org/10.1136/jitc-2022-004713

Ejemplares similares